MDMA (3,4-methylenedioxy-N-methylamphetamine) for the treatment of tinnitus

Two-phase, placebo-controlled, double-blind crossover study assessing oral low-dose MDMA versus placebo in people with constant tinnitus; phase 1 evaluates 30 mg (and 70 mg if needed) and phase 2 further assesses the selected dose in a larger sample.

Sessions occur in a low-sensory environment under pharmacist supervision; phase 2 includes resting-state fMRI before and two hours after administration to objectively assess MDMA effects.